(Reuters) – Johnson & Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday.
The company has previously said the vaccine will be available on a not-for-profit basis until the end of the pandemic.
(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva)
